Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ebola

Ebola

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ebola

15 trials tracked for Ebola: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 1605 citations.

15Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 7 Phase 1 5
  1. Phase 3 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Completed · 1,605 cited
  2. Phase 3 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Completed · 96 cited
  3. Phase 3 A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants Completed
  4. Phase 2 A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants Completed
  5. Phase 2 Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) Completed
  6. Phase 2 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Completed
Show 9 more trials
  1. Phase 2 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Completed
  2. Phase 2 Partnership for Research on Ebola VACcinations Completed
  3. Phase 2 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection Completed
  4. Phase 2 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Completed
  5. Phase 1 Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination Completed
  6. Phase 1 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults Completed
  7. Phase 1 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) Completed
  8. Phase 1 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) Completed
  9. Phase 1 A Study of a New Vaccine Against Two Types of Ebola Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Ebola: what the trials found

The Ad26.ZEBOV vaccine has demonstrated significant immunogenicity, with a high percentage of participants showing an Ebola Virus Glycoprotein (GP-EBOV) antibody response (p<0.001) 7. In Phase 3 trials, the vaccine elicited substantial binding antibody levels against EBOV GP at 21 days post-vaccination 4, and safety data indicated varying rates of solicited local and systemic adverse events within 7 days of dosing 6.

Therapeutic interventions include ZMapp, which was evaluated in a Phase 3 trial regarding the time to first negative Ebola Virus RT-PCR in blood 2.

Recent results — preliminary, needs further review

  • The V920 (rVSVΔG-ZEBOV-GP) vaccine induced high geometric mean titers of 8,416.0 and 40.3 (p<0.001) in a Phase 2 trial 1.

For the clinician treating this condition

  • Ad26.ZEBOV is established as an immunogenic vaccine for Ebola, showing significant GP-EBOV antibody responses 7.
  • The V920 vaccine has demonstrated high geometric mean titers in Phase 2 testing 1.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
rVSVΔG-ZEBOV-GP induces over 40-fold increase in GP-ELISA antibody response in HIV patients
Infectious Disease RCT
rVSVΔG-ZEBOV-GP induces over 40-fold increase in GP-ELISA antibody response in HIV patients Trial shows vaccine triggers strong response in people with HIV
This Phase 2 randomized controlled trial evaluated rVSVΔG-ZEBOV-GP in 251 adults and adolescents with HIV on antiretroviral therapy. The vac…
A new vaccine trial shows that people living with HIV can develop strong defenses against the Ebola virus after receiving a single dose.
Oct 4, 2026
Ervebo and Zabdeno/Mvabea vaccines show significant differences in antibody cross-reactivity to Bundibugyo virus
Infectious Disease Meta-analysis
Ervebo and Zabdeno/Mvabea vaccines show significant differences in antibody cross-reactivity to Bundibugyo virus Ebola vaccines show limited protection against Bundibugyo virus disease
This meta-analysis evaluates antibody cross-reactivity and protection against Bundibugyo virus (BDBV) following Ervebo or Zabdeno/Mvabea vac…
New data shows that while some Ebola vaccines provide some protection against Bundibugyo virus, the level of cross-protection is quite limit…
medRxiv Sep 16, 2026
One Health diagnostics improve pathogen detection and outbreak prediction through cross-sector collaboration and technological innovation
Psychiatry Sys. Review
One Health diagnostics improve pathogen detection and outbreak prediction through cross-sector collaboration and technological innovation One Health approach could stop future pandemics before they start
This structured narrative review examines One Health diagnostic strategies to address zoonotic diseases including SARS, Ebola, and COVID-19.…
A new review shows that combining human, animal, and environmental health monitoring can catch outbreaks like SARS and COVID-19 earlier.
Frontiers Jul 28, 2026
Environmental and social factors influence arbovirus proliferation in changing climate conditions
Infectious Disease Cohort
Environmental and social factors influence arbovirus proliferation in changing climate conditions Rising Temperatures Push Dangerous Viruses Into New Communities
This review examines how environmental and social factors, including increasing temperatures and urbanization, affect the proliferation of a…
Warming weather pushes dangerous insect-borne viruses into new areas, making early warning systems and vaccines more critical than ever for …
Frontiers Apr 28, 2026
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection
Genetics & Precision Medicine Cohort
EBOV-specific gene signature identified in nonhuman primates and human cohorts with Ebola infection New gene signature can spot Ebola infection in blood samples
This observational cohort study analyzed RNA-Seq data from nonhuman primates and human cohorts with Ebola virus infection and comparator inf…
Researchers found a 50-gene signature that reliably separates Ebola from other infections in blood tests, pointing to a future diagnostic to…
Frontiers Apr 23, 2026
Preclinical modeling study on COVID-19 and Ebola epidemic dynamics and interventions
Infectious Disease
Preclinical modeling study on COVID-19 and Ebola epidemic dynamics and interventions Cities Spread Disease Faster — Here’s What Helps
This is a preclinical modeling study using a UK-based spatial metapopulation SEIR framework to simulate COVID-19 and Ebola outbreaks.
This new tool could help leaders slow epidemics before they explode.
medRxiv Apr 23, 2026
Review examines repurposing Ebola vaccines, but evidence details are unavailable
Infectious Disease
Review examines repurposing Ebola vaccines, but evidence details are unavailable Researchers explore whether existing Ebola vaccines could be repurposed
A review article discusses the concept of repurposing Ebola vaccines.
Scientists are investigating whether vaccines originally developed for Ebola could be used for other purposes.
CDC Apr 4, 2026

Questions about Ebola

What interventions are modeled for stopping the Ebola epidemic?

Models show Ebola stops through isolation, expanding treatment beds, community engagement, and managing viral persistence in survivors.

Full answer →
How do social factors influence the spread of Ebola?

Social factors like human movement, community trust, and how people perceive risk directly change how fast Ebola spreads and how hard it is to stop.

Full answer →